October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
AML Relapse Predictive Ability of ctDNA Comparable With Bone Marrow Mutation Persistence
October 15th 2019Among patients with acute myeloid leukemia and myelodysplastic syndrome who completed myeloablative allogeneic hematopoietic stem cell transplantation, the predictive utility of testing circulating tumor DNA was comparable with that of mutation persistence evaluation in matched bone marrow samples, according to a study published recently in Blood.
Read More
Pro Discusses Options for Patients With Advanced-Stage Hodgkin Lymphoma
October 10th 2019Barbara Pro, MD, spoke with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion about the diagnosis, prognosis, and treatment of patients with Hodgkin lymphoma based on the case of a young woman with classic Hodgkin lymphoma.
Read More
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 7th 2019Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Watch
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
Duvelisib Gains FDA Orphan Drug Designation for T-Cell Lymphomas
October 4th 2019The FDA has granted duvelisib with an orphan drug designation for the treatment of patients with T-cell lymphoma, according to a press release from Verastem Oncology, the company developing duvelisib.<br />
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
Blinatumomab Trials Stopped After Benefit is Observed in Pediatric ALL
October 2nd 2019Due to treatment benefit observed in pediatric patients with acute lymphoblastic leukemia, 2 clinical trials investigating blinatumomab (Blincyto) versus chemotherapy were stopped early, according to the drug developer Amgen.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Durable Responses Demonstrated in Phase I/II With U2 Triplet Regimen in CLL
September 28th 2019Umbralisib and ublituximab in combination with pembrolizumab was well tolerated among patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation, according to a phase I/II trial presented at the 18th International Workshop on CLL. Responses were durable in high-risk patients who are BTK-refractory, including 2 complete responses in patients with RT.
Read More
Real-World Tisagenlecleucel Data Match Trial Results in Patients With ALL and DLBCL
September 25th 2019In an interview with <em>Targeted Oncology</em>, Marcelo C. Pasquini, MD, discussed the importance of obtaining real-world data and establishing registries for collecting patient outcomes, and how real-world data compare with data from pivotal trials. He also explained the challenges with accessibility to CAR T-cell therapies.
Read More
Favorable Safety Profile Demonstrated With Umbralisib in Pretreated CLL
September 25th 2019The PI3K-delta inhibitor umbralisib demonstrated a favorable toxicity profile as treatment for patients with chronic lymphocytic leukemia who have become intolerant to a prior kinase inhibitor, of either BTK or PI3K inhibition, according to results from a phase II study presented at the 18th International Workshop on CLL.
Read More
Acalabrutinib Shows High Response, Prolonged Survival in Ibrutinib-Intolerant R/R CLL
September 24th 2019Bruton tyrosine kinase inhibitor acalabrutinib demonstrated a high rate of response, prolonged survival, and high tolerability in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib. Findings were presented at the 15th International Conference on Malignant Lymphoma.
Read More
Annual Hematology Meeting Cochair Encourages Embracing of CAR T-Cell Therapy
September 24th 2019Now in it 24th year, the annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma, hosted by Physicians’ Education Resource, LLC, continues to bring significant advances in hematology to the forefront.
Read More
Experts Debate Best Strategies for Early-Relapsing Follicular Lymphoma
September 20th 2019"Early-relapsing lymphoma is a problem, there is no debate about that. The hard part is in trying to manage these patients effectively,” Jonathon B. Cohen, MD, MS, told an audience at the 2019 Debates and Didactics in Hematology and Oncology conference held in Sea Island, Georgia.<br />
Read More
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
September 20th 2019Chronic myeloid leukemia is a rare type of cancer, and tyrosine kinase inhibitors have become the standard guideline-recommended treatment for patients with <em>BCR-ABL1</em>–positive or Ph-positive CML.
Read More
Expert Highlights Frontline Advancements in Treatment Landscape for CML
September 19th 2019In an interview with <em>Targeted Oncology</em>, Neil P. Shah, MD, PhD, discussed the latest advancements in the treatment landscape of chronic myeloid leukemia, including the introduction of tyrosine kinase inhibitors. He also addressed some of the challenges both oncologists and patients face in this space.<br />
Read More
FLT3 Inhibitors Impact Treatment Landscape for Patients With FLT3-Mutated AML
September 18th 2019Gail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.
Watch
Genetic Analysis Provides Insight Into Venetoclax/Obinutuzumab Benefit in Frontline CLL
September 18th 2019Rate of response and progression-free survival were superior with venetoclax versus chlorambucil in patients with chronic lymphocytic leukemia who also received obinutuzumab, and this trend was observed across all genetic subgroups.<br />
Read More
Novel Combination Therapies in CLL Transform the Treatment Landscape
September 15th 2019The presence of novel combinations and oral targeted therapies are rising in the frontline treatment setting for patients with chronic lymphocytic leukemia, regardless of age. According to Nitin Jain, MD, ongoing phase III trials will bring additional modifications to the treatment landscape.
Read More
Expert Says Immunotherapy in AML Expanded to New Approaches, Despite Challenges
September 14th 2019In an interview with <em>Targeted Oncology </em>during the 2019 SOHO Annual Meeting, John F. DiPersio, MD, PhD, discussed the challenges in research surrounding immunotherapies for AML, including DARTs, BiTEs, ADCs, and CARs.
Read More
Improvement in PFS Shown With Checkpoint Inhibition Before Transplantation in R/R Hodgkin Lymphoma
September 13th 2019In a retrospective study of patients with replaced or refractory Hodgkin lymphoma, checkpoint inhibition prior to haploidentical stem cell transplantation improved progression-free survival and risk for relapse, based on results presented at the 2019 SOHO Annual Meeting.
Read More
Novel Agent CC-486 Demonstrates OS Benefit in AML First-Line Maintenance
September 13th 2019In the phase III QUAZAR AML-001 trial, an investigational oral azacitidine therapy, CC-486, induced a statistically significant improvement in overall survival compared with placebo when used as a maintenance therapy in the treatment of patients with newly diagnosed acute myeloid leukemia who achieved a complete response or CR with incomplete blood count recovery following treatment with induction chemotherapy.
Read More